Startup
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round GILZRx raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
Companies GILZRx acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Sarah Jones | Founder | Startup Daily, Brandon Capital |
Stories naming GILZRx. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon BioCatalyst's CUREator incubator has granted an extra $1.865m across four Australian biotechs working on antibiotic prescribing, schizophrenia, muscular dystrophy and autoimmune therapies, on top of their initial awards.
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.